About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Monthly Archives: April 2007
Cheers all! It is time for the Weekly Roundup – where I overview several of the events from the week. I’ve been in London all week where the weather has been much nicer than anything that was happening in windy, … Continue reading
The answer is probably simple. The answer is probably everyone. I think all can agree on that. This week, as PDUFA is being discussed on the Hill, Consumer Reports released a poll of approximately 1000 individuals in a phone … Continue reading
The pharmaceutical industry has been slow to embrace new media. There are a number of good reasons for this. Any highly regulated industry, such as the pharmaceutical industry, has to be careful and concerned when considering new media strategies. That … Continue reading
There have been several proposals before Congress which, in one way or another, have the potential to impact the amount of direct-to-consumer advertising (DTC) allowed. Some would give the FDA authority to restrict such advertising. Others have called for it … Continue reading
Since I have been working in healthcare public affairs, there has been a tremendous shift in the way that communications teams need to think about supporting products in the market place. It occurs to me that earlier and earlier in … Continue reading